6-Amino-5-chloro-N-[(1S)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-4-pyrimidinecarboxamide | 1096708-73-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-Amino-5-chloro-N-[(1S)-1-[5-[[[5-chloro-4-(trifluoromethyl)-2-pyridinyl]amino]carbonyl]-2-thiazolyl]ethyl]-4-pyrimidinecarboxamide
• 英文别名: 2-[(1S)-1-[(6-amino-5-chloropyrimidine-4-carbonyl)amino]ethyl]-N-[5-chloro-4-(trifluoromethyl)pyridin-2-yl]-1,3-thiazole-5-carboxamide
• CAS: 1096708-73-4
• 化学式: C₁₇H₁₂Cl₂F₃N₇O₂S
• 分子量: 506.3
• InChiKey: VWMJHAFYPMOMGF-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  164
• 氢给体数：
  3
• 氢受体数：
  11

文献信息

• COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
  申请人：Chen Weirong

  公开号：US20090036419A1

  公开（公告）日：2009-02-05

  The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

  本发明提供了作为Raf蛋白激酶抑制剂有用的化合物。本发明还提供了这些化合物的组合物，以及治疗Raf介导疾病的方法。
• Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US10426782B2

  公开（公告）日：2019-10-01

  The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.

  本发明涉及一种包含化合物 1 或其药学上可接受的盐的用于治疗癌症的药物组合物及其制备方法。本发明还涉及按照间歇给药方案将药物组合物给患者用药。
• PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP2167489B1

  公开（公告）日：2017-05-03
• THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS
  申请人：Sunesis Pharmaceuticals, Inc.

  公开号：EP3231798B1

  公开（公告）日：2019-10-09
• PHARMACEUTICAL FORMULATIONS OF A PAN-RAF KINASE INHIBITOR, PROCESSES FOR THEIR PREPARATION, AND METHODS OF USE
  申请人：MILLENNIUM PHARMACEUTICALS,INC.

  公开号：US20170173033A1

  公开（公告）日：2017-06-22

  The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.